OCT 0 8 2004

SEQUENCE LISTING

odgers, Kathleen E. diZerega, Gere S.

```
<120> Use of Angiotensin II Fragments and Analogs Thereof in Tissue
<130> 00-1188-E1-A
<140> 10/667,066
<141> 2003-09-18
<150> 09/723,437
<151> 2000-11-28
<150> 09/608,532
<151> 2000-06-30
<150> 09/208,337
<151> 1998-12-09
<150> 08/465,775
<151> 1995-06-06
<150>
      08/337,781
<151> 1994-11-14
<150> 08/126,368
<151> 1993-09-24
<160> 21
<170> PatentIn version 3.3
<210> 1
<211>
      8
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 1
Asp Arg Val Tyr Ile His Pro Phe
<210> 2
<211>
<212> PRT
<213> Artificial
```

<220>

<223> Synthetic peptide

<400> 2

Arg Val Tyr Ile His Pro Phe

```
5
1
<210> 3
<211> 6
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 3
Val Tyr Ile His Pro Phe
<210> 4
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 4
Asp Arg Val Tyr Ile His Pro
<210> 5
<211> 6
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 5
Arg Val Tyr Ile His Pro
<210> 6
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 6
Val Tyr Ile His Pro
```

<210> 7

```
<211> 4
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 7
Ile His Pro Phe
<210> 8
<211> 6
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 8
Asp Arg Val Tyr Ile His
<210> 9
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 9
Asp Arg Val Tyr Ile
<210> 10
<211> 4
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 10
Asp Arg Val Tyr
<210> 11
<211> 3
<212> PRT
<213> Artificial
```

```
<220>
<223> Synthetic peptide
<400> 11
Asp Arg Val
<210> 12
<211> 3
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 12
His Pro Phe
<210> 13
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 13
Tyr Ile His Pro Phe
<210> 14
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<220>
<221> MISC FEATURE
<222> (1)..(1)
<223> Xaa is H, Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg, or D-Lys
<220>
<221> MISC FEATURE
<222> (2)..(2)
<223> Xaa is Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc, or Tyr
<220>
<221> MISC FEATURE
<222> (4)..(4)
<223> Xaa is Ile, Ala, Leu, Val, or Gly
                                      Page 4
```

```
<400> 14
Xaa Xaa Tyr Xaa His Pro Phe
<210> 15
<211> 8
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<220>
<221> MISC_FEATURE
<222>
      (1)..(1)
<223> Xaa is Asp, Glu, Asn, Acpc, Ala, Me2Gly, Pro, Bet, Glu(NH2), Gly,
       Asp(NH2), or Suc
<220>
<221> MISC FEATURE
<222>
      (2)..(2)
<223> Xaa is Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg, or D-Lys
<220>
      MISC FEATURE
<221>
<222>
      (3)..(3)
<223> Xaa is Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc, or Tyr
<220>
<221> MISC FEATURE
<222>
      (4)..(4)
<223> Xaa is Tyr, Thr, Ser, or azaTyr
<220>
<221> MISC_FEATURE
<222>
      (5)...(5)
<223> Xaa is Ile, Ala, Leu, Val, or Gly
<220>
<221> MISC FEATURE
<222>
      (6)..(6)
<223> Xaa is His or Arg
<220>
<221> MISC FEATURE
<222> (7)..(7)
<223> Xaa is Pro or Ala
<220>
<221> MISC_FEATURE
      (8)..(8)
<222>
      Xaa is Phe, Phe(Br), Ile, or Tyr
<400> 15
```

Xaa Xaa Xaa Xaa Xaa Xaa Xaa

```
1
<210> 16
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 16
Asp Arg Val Gly Gly Gly Gly
                5
<210> 17
<211> 6
<211> 0
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 17
Gly Gly Gly Asp Arg Val
<210> 18
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 18
Arg Val Tyr Ile His Pro Lys Lys
<210> 19
<211> 11
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<400> 19
Lys Lys Lys Lys Arg Val Tyr Ile His Pro
```

```
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<220>
<221> MOD_RES
<222> (1)..(1)
<223> D-Ala
<400> 20
Ala Ile His Pro Phe
               5
<210> 21
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<220>
<221> MOD_RES 
<222> (5)..(5)
<223> D-Ala
<400> 21
Ile His Pro Phe Ala
```